LeMaitre Vascular (NASDAQ:LMAT) Updates FY 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.930-3.080 for the period, compared to the consensus earnings per share estimate of 2.900. The company issued revenue guidance of $277.0 million-$283.0 million, compared to the consensus revenue estimate of $279.5 million. LeMaitre Vascular also updated its Q2 2026 guidance to 0.790-0.840 EPS.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Citizens Jmp increased their price objective on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. Barrington Research increased their price objective on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Freedom Capital upgraded shares of LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Finally, Zacks Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $105.80.

LeMaitre Vascular Stock Performance

LMAT stock traded up $0.47 during midday trading on Tuesday, hitting $112.00. 225,462 shares of the stock traded hands, compared to its average volume of 173,958. The firm has a market cap of $2.56 billion, a P/E ratio of 44.62, a PEG ratio of 3.21 and a beta of 0.60. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95. The stock’s fifty day simple moving average is $109.28 and its 200-day simple moving average is $94.17. LeMaitre Vascular has a 1-year low of $78.35 and a 1-year high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.66 by $0.02. The company had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The firm’s revenue was up 11.1% on a year-over-year basis. During the same quarter last year, the business earned $0.48 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, analysts expect that LeMaitre Vascular will post 2.89 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 26th. Investors of record on Thursday, March 12th were given a dividend of $0.25 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 annualized dividend and a yield of 0.9%. The ex-dividend date was Thursday, March 12th. LeMaitre Vascular’s dividend payout ratio (DPR) is 39.84%.

Insider Activity at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 1,044 shares of LeMaitre Vascular stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $110.29, for a total value of $115,142.76. Following the sale, the insider owned 6,677 shares in the company, valued at $736,406.33. This trade represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David B. Roberts sold 8,464 shares of LeMaitre Vascular stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $106.80, for a total transaction of $903,955.20. Following the completion of the sale, the director owned 17,979 shares in the company, valued at approximately $1,920,157.20. This trade represents a 32.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 215,438 shares of company stock worth $23,062,911. 7.40% of the stock is owned by company insiders.

Key Stories Impacting LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Earnings beat and year-over-year EPS growth — LMAT reported Q1 EPS of $0.68 vs. the Zacks consensus $0.66 and $0.48 a year ago, indicating margin strength and operating leverage. LeMaitre Vascular (LMAT) Tops Q1 Earnings Estimates
• Positive Sentiment: Management raised EPS guidance — LMAT set Q2 2026 EPS guidance of $0.79–$0.84 (above consensus $0.76) and FY2026 EPS guidance of $2.93–$3.08 (above consensus ~$2.90), signaling confidence in demand and near-term profitability. View Press Release
• Positive Sentiment: Dividend declared — the company announced a quarterly cash dividend of $0.25/share, which supports income-focused investors and can be viewed as a sign of cash-generative business. LeMaitre Q1 2026 Financial Results
• Positive Sentiment: Strong profitability metrics — Q1 net margin (~23.1%) and ROE (~14.7%) underline efficient operations and support the elevated EPS outlook. View Press Release
• Neutral Sentiment: Revenue roughly in line with expectations — Q1 revenue was $66.55M versus consensus ~$66.67M, effectively in line; this tempers but does not negate the EPS beat. LeMaitre (NASDAQ:LMAT) Posts Q1 CY2026 Sales In Line With Estimates
• Neutral Sentiment: Revenue guidance band roughly matches consensus — FY revenue guidance $277M–$283M brackets street estimates (~$279.5M), so upside is more EPS-driven than revenue-driven at this point. View Press Release
• Negative Sentiment: Minor revenue shortfall vs. consensus — Q1 revenue missed by about $0.12M (66.55M vs. 66.67M), which is immaterial in isolation but worth watching if the trend continues. View Press Release

Institutional Trading of LeMaitre Vascular

Several institutional investors have recently modified their holdings of LMAT. First Trust Advisors LP raised its stake in shares of LeMaitre Vascular by 13.4% in the 4th quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock valued at $76,245,000 after acquiring an additional 111,193 shares during the period. State Street Corp raised its stake in shares of LeMaitre Vascular by 0.8% in the 4th quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock valued at $65,447,000 after acquiring an additional 6,130 shares during the period. Geode Capital Management LLC raised its stake in shares of LeMaitre Vascular by 20.1% in the 4th quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock valued at $51,351,000 after acquiring an additional 105,921 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of LeMaitre Vascular by 2.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 475,845 shares of the medical instruments supplier’s stock valued at $38,594,000 after acquiring an additional 13,166 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of LeMaitre Vascular by 144.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock valued at $31,731,000 after acquiring an additional 231,157 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.